Immix Biopharma, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 9, 2024. The unaudited consolidated statements include Immix and its subsidiaries. Immix is a clinical-stage biopharmaceutical company developing cell therapies; it has not generated revenue from operations.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 or comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Operating expenses | $5.59 million | $2.52 million |
| Research and development | $3.25 million | $1.32 million |
| General and administrative | $2.34 million | $1.20 million |
| Net loss | $5.33 million | $2.50 million |
| Loss per share, basic and diluted | $0.22 | $0.18 |
| Net cash used in operating activities | $3.83 million | $2.09 million |
| Cash and cash equivalents, March 31 | $29.32 million | $17.51 million at December 31, 2023 |
| Working capital, March 31 | $27.3 million | Prior comparable-period figure not provided |
| Total liabilities, March 31 | $6.72 million | $3.72 million at December 31, 2023 |
Margins are not meaningful because the company reported no revenue. The filing reports no conventional borrowing; liabilities include $1.09 million of operating lease obligations. Q1 investing cash outflow was $0.30 million, primarily for property and equipment. Financing activities provided $15.95 million, largely from the February public offering and its exercised over-allotment option.
Material changes versus the prior comparable period
- Net loss more than doubled, mainly as R&D expense increased with ongoing clinical-trial activity and G&A rose with higher professional services, investor-relations costs, and stock-based compensation.
- Operating cash use increased from $2.09 million to $3.83 million.
- Cash increased from $17.51 million at year-end 2023 to $29.32 million at quarter-end, primarily reflecting Q1 equity financing.
- In February and March, the company issued 6,319,025 shares through a public offering and over-allotment, receiving approximately $15.52 million net. It also raised $0.34 million net through ATM sales during Q1, then suspended sales under that prospectus supplement on February 5.
Outlook, management commentary, and risks
- Management estimated that cash on hand at March 31 would fund working-capital needs through at least May 9, 2025; elsewhere the filing says cash and potential Sales Agreement proceeds should fund planned operations for at least 12 months from the filing date. These are estimates, not assurance of adequate funding.
- The company expects continued operating losses and negative operating cash flows and says it will need additional capital. It has no credit facility or committed sources of capital. Future equity financing could dilute shareholders; other financing arrangements could require relinquishing rights.
- Lead candidate NXC-201 is being evaluated in the Phase 1b/2a NEXICART-1 trial for relapsed/refractory AL amyloidosis and other indications. The company reported that, as of February 2024, 10 AL amyloidosis patients in the trial had an overall response rate of 100% and complete response rate of 70%; these are early company-reported clinical results, not established approval or commercial outcomes.
- The company entered a non-cancelable lease for approximately 14,000 square feet of California manufacturing space, expiring in December 2033; Q1 construction in progress included $0.31 million for facility improvements. The HADASIT/BIRAD license also entails approximately $13 million in additional quarterly payments through September 2026, plus annual fees and potential royalties and milestones.
- Management identified disclosure controls as ineffective at March 31 because of a material weakness involving limited personnel and insufficient formal accounting processes, including journal-entry processing and review. The company said it is using accounting consultants and continuing remediation efforts.
- The filing reports no pending litigation it believes material and no material changes to previously disclosed risk factors, while highlighting financing access, clinical and regulatory development, competition, intellectual-property, third-party, and dilution risks.
Most important facts for investors to verify
- Updated NXC-201 trial enrollment, safety, response durability, and whether interim results are confirmed in larger patient groups.
- Cash burn, actual runway, and the timing and terms of any additional financing; the July ATM prospectus supplement was suspended.
- Potential dilution from the public offering, 1,913,661 pre-funded warrants, other warrants, and 2,511,310 stock options outstanding at quarter-end.
- Progress and costs for the manufacturing facility and continuing HADASIT/BIRAD license and clinical-trial obligations.
- Whether management remediates the disclosed material weakness and improves disclosure controls.